{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:10:18Z","timestamp":1790349018609,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rpth.2025.103229","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:46:53Z","timestamp":1761187613000},"page":"103229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Haemophilia B: an illustrative review of current challenges and opportunities"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"Cedric","family":"Hermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonata \u0160aulyt\u0117","family":"Trakymien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103229_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0033-1353996","article-title":"Hemophilia A and hemophilia B: different types of diseases?","volume":"39","author":"Santagostino","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2025.103229_bib2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.103229_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rpth.2025.103229_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100018","article-title":"Thrombin generation and implications for hemophilia therapies: a narrative review","volume":"7","author":"Sidonio","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103229_bib5","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1213\/ane.0b013e31819bceb1","article-title":"The role of tissue factor and factor VIIa in hemostasis","volume":"108","author":"Mackman","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1016\/j.rpth.2025.103229_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/a-1945-9429","article-title":"Insights into the molecular genetic of hemophilia A and hemophilia B: the relevance of genetic testing in routine clinical practice","volume":"42","author":"Pezeshkpoor","year":"2022","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2025.103229_bib7","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.3390\/ijms23052762","article-title":"The molecular basis of FIX deficiency in hemophilia B","volume":"23","author":"Shen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rpth.2025.103229_bib8","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103229_bib9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.hoc.2021.07.008","article-title":"Hemophilia B (factor IX deficiency)","volume":"35","author":"Sidonio","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.rpth.2025.103229_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.985975","article-title":"Fragile sites, chromosomal lesions, tandem repeats, and disease","volume":"13","author":"Mirceta","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.rpth.2025.103229_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3727\/215517912X639496","article-title":"Hepatocyte is a sole cell type responsible for the production of coagulation factor IX in vivo","volume":"3","author":"Tatsumi","year":"2012","journal-title":"Cell Med"},{"key":"10.1016\/j.rpth.2025.103229_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.rpth.2025.103229_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720966888","article-title":"Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review","volume":"11","author":"Hermans","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2025.103229_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/hae.14324","article-title":"Plasma factor IX: the tip of the iceberg?","volume":"27","author":"Sidonio","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","article-title":"Advances in the management of haemophilia: emerging treatments and their mechanisms","volume":"28","author":"Okaygoun","year":"2021","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.rpth.2025.103229_bib17","article-title":"Gene therapy for hemophilia: facts and quandaries in the 21st century","volume":"12","author":"Arruda","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.rpth.2025.103229_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12695","article-title":"Impact of novel hemophilia therapies around the world","volume":"6","author":"Ozelo","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103229_bib20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1126\/science.1180660","article-title":"Genotype analysis identifies the cause of the \"royal disease.\"","volume":"326","author":"Rogaev","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.rpth.2025.103229_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.blre.2017.08.007","article-title":"Haemophilia B: where are we now and what does the future hold?","volume":"32","author":"Dolan","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2025.103229_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/hae.14983","article-title":"Women and girls with inherited bleeding disorders: focus on haemophilia carriers and heavy menstrual bleeding","volume":"30","author":"Hermans","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hae.14675","article-title":"Association of factor expression levels with annual bleeding rate in people with haemophilia B","volume":"29","author":"Burke","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/hae.12470","article-title":"Similar bleeding phenotype in young children with haemophilia A or B: a cohort study","volume":"20","author":"Clausen","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/hae.14525","article-title":"Quality of life in a large multinational haemophilia B cohort (the B-Natural study) \u2013 unmet needs remain","volume":"28","author":"Berntorp","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/PROM.S214188","article-title":"Mild-severe hemophilia B impacts relationships of US adults and children with hemophilia B and their families: results from the B-HERO-S study","volume":"10","author":"Cutter","year":"2019","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.rpth.2025.103229_bib27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/ejh.13055","article-title":"Impact of hemophilia B on quality of life in affected men, women, and caregivers\u2014assessment of patient-reported outcomes in the B-HERO-S study","volume":"100","author":"Buckner","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2025.103229_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12741","article-title":"Socioeconomic participation of persons with hemophilia: results from the sixth hemophilia in the Netherlands study","volume":"6","author":"van Balen","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103229_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib30","first-page":"364","article-title":"Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?","volume":"11","author":"den Uijl","year":"2013","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2025.103229_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.103229_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2040620718802606","article-title":"Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B","volume":"9","author":"Mahlangu","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2025.103229_bib33","article-title":"Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B","volume":"2","author":"Olasupo","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpth.2025.103229_bib34","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/blood.2023021944","article-title":"Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2025.103229_bib35","first-page":"102925","article-title":"Oral communications abstracts [abstract]","volume":"9","author":"Porello","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103229_bib36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103229_bib37","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2025.103229_bib38","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","article-title":"Sustained clinical benefit of AAV gene therapy in severe hemophilia B","volume":"392","author":"Reiss","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103229_bib39","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1038\/s41598-017-04625-5","article-title":"CRISPR\/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice","volume":"7","author":"Ohmori","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.rpth.2025.103229_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221085202","article-title":"International consensus recommendations on the management of people with haemophilia B","volume":"13","author":"Hart","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2025.103229_bib41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","volume":"111","author":"Chowdary","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2025.103229_bib42","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.103229_bib43","series-title":"Medications in single-dose vials: implications of discarded drugs","author":"Nass","year":"2021"},{"key":"10.1016\/j.rpth.2025.103229_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/10600280231170650","article-title":"Fixed versus body-sized-based dosing of monoclonal antibodies","volume":"58","author":"Erstad","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rpth.2025.103229_bib45","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpth.2025.103229_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100890","article-title":"Hemophilia treatment in 2021: choosing the \"optimal\" treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians","volume":"52","author":"Hermans","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2025.103229_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231165857","article-title":"Considerations for shared decision management in previously untreated patients with hemophilia A or B","volume":"14","author":"Astermark","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2025.103229_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101098","article-title":"The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators","volume":"61","author":"Goedhart","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2025.103229_bib49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2025.103229_bib50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2516.2011.02436.x","article-title":"A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B","volume":"17","author":"Recht","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hae.14193","article-title":"Current challenges for men and women with mild-to-moderate haemophilia","volume":"27","author":"Rajpurkar","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib52","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/jth.15424","article-title":"Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019","volume":"19","author":"Hassan","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103229_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2020.02.011","article-title":"Simplifying surgery in haemophilia B: low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP","volume":"188","author":"Curtin","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103229_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2012.02822.x","article-title":"WFH: closing the global gap--achieving optimal care","volume":"18","author":"Skinner","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-3148.2001.00315.x","article-title":"The relationship between ABO histo-blood group, factor VIII and von Willebrand factor","volume":"11","author":"O\u2019Donnell","year":"2001","journal-title":"Transfus Med"},{"key":"10.1016\/j.rpth.2025.103229_bib56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14737167.2016.1178066","article-title":"An innovative outcome- based care and procurement model of hemophilia management","volume":"16","author":"Gringeri","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.rpth.2025.103229_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12567","article-title":"Living with a \"hemophilia-free mind\" \u2013 the new ambition of hemophilia care?","volume":"5","author":"Krumb","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103229_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14535","article-title":"Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues","volume":"28","author":"Weyand","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hae.13502","article-title":"Women with bleeding disorders","volume":"24","author":"Hermans","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103229_bib60","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1182\/bloodadvances.2024013866","article-title":"Proactive systematic hemophilia carrier screening: a step towards gender equity in hemophilia care","volume":"8","author":"Krumb","year":"2024","journal-title":"Blood Adv"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:32:20Z","timestamp":1766129540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925005539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2475037925005539"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103229","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haemophilia B: an illustrative review of current challenges and opportunities","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103229"}}